Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormo...(medical products for the treatment of se...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product
Date:12/16/2008
medical products for the treatment of serious unmet medical needs.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at www.bolderbio.com.
Statements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.
'/>"/>
| SOURCE Bolder BioTechnology, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
2. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
3. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
4. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
5. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
6. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
7. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
8. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
9. Leading Biotechnology Company Grows with StayinFront CRM
10. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
11. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
Post Your Comments:
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNew...y guidance document for the publication of company...line today by the British Medical Journal (BMJ). "...on of the importance of providing support and guid...cation of study results in the peer-reviewed medic...
(Date:11/30/2009)..., CHICAGO, Nov. 30 Dr. Jessica ...ge Washington University Medical Center in Washing... Breast-Specific Gamma Imaging (BSGI) in clinical ...agnosis of breast cancer today at the annual meeti...SNA). ,, "The purpose of the exhibit was to dem...
(Date:11/30/2009)... , ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCa...day it has completed enrollment in the Phase II cl...2008/2009 recommended strains) VLP vaccine candida...er adults). This randomized, double-blind, active...ility and immunogenicity of two different doses (1...
(Date:11/30/2009)... PDS, a leader in providing sma...nity, announces Pajama Pathology®, evolutioniz... same ‘gold standard’ software used by...orld, but on a ‘cost per slide’ basis....RWEB) November 30, 2009 -- PDS has announced anoth...
Breaking Biology Technology:ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3[1] ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ[0] Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer[0] NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults[0] Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS
... Increased 5-Year Survival Data for Responding Pat...rporated (OTC Bulletin Board: GNTA) announced that...d and Drug Administration (FDA) for its,New Drug A...um) Injection,plus chemotherapy for patients with ...a (CLL). The submission is based on new informatio...
...June 6 DURECT Corporation,(Nasdaq: DRRX ) announ...at,three upcoming life sciences conferences in New...gy and Medical Technology Conference on Thursd...,s Pain Roundtable Conference, on Monday, June 23r... Healthcare Conference on Thursday, June 26th at ...
...une 6 InterMune, Inc.,(Nasdaq: ITMN ) today anno...,Chief Financial Officer of InterMune, will presen...Healthcare Conference in Dana Point, Calif. on,Jun...Hodgman will also,present at the Seventh Annual Ne...hnology Conference in New York on June 12, 2008 at...
Other Biology Technology:Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 2Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 3Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia 4InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences 2(Date:11/26/2009)... survey carried out in eight European countries ha...fectious disease pandemic could have a significant...s writing in the open access journal BMC Infectio...on school days and weekends/holidays, finding that... Hens, from Hasselt and Antwerp University, Belgiu...
(Date:11/26/2009)...RSA (methicillin-resistant Staphylococcus Aureus ...ihilation as low-temperature plasma prototype devi... and unfailing bactericidal cocktails. , Two pro...ent disinfection of healthy skin (e.g. hands and f... can pose a lethal threat; and another to shoot ba...
(Date:11/25/2009)...thens, Ga. Bacteria don,t have easy lives. In add... bugs, they have natural enemies called bacterioph... every two days. , Still, bacteria and another ...overed in extreme environments such as deep-sea vo... because they have a built-in defense system that ...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 1Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 2Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference 49329 3Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 1Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 2Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin 49327 3EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 1EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 2EUCODIS Bioscience Achieves Development Milestone in Second Collaboration With Lohmann Animal Health 4613 3... 23, 2007, President Bush stated that, in order to... increase the supply of alternative fuels, by sett...on gallons of renewable and alternative fuels in 2...l refiner subsidy promised in the 2008 Farm Bill a... growers are putting energy needs ahead of environ...
...th breast cancer today are candidates for lumpecto...ast tissue. Results of a UC Davis study, however, ... the same breast are treated with a second lumpect...tment recommendations and cutting the number of ye...rised to find that so many women in our study alm...
...r undertaken of the upper U.S. Gulf Coast suggests...rs could flood large swaths of wetlands this centu...In terms of sea-level increases and river sediment... a time when bays will face conditions they last s...ears ago," said lead researcher John Anderson, the...
Other Biology News:Mandate for biofuels production requires science-based policy and global perspective 2Second lumpectomy for breast cancer reduces survival rates 2Bays on US Gulf Coast vulnerable to flooding 2Rat Anti-p19ARF Monoclonal Antibody, Unconjugated, Clone 5-C3-1 from Upstate
EDTA, tetrasodium salt from GE Healthcare, formerly Amersham Biosciences
Tracker Datamatrix RS-1* from Micronic BV
GeneAmplimer HIV-1 Control Reagents from Applied Biosystems
Biology Products:| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |